Nimotuzumab Plus Paclitaxel and Cisplatin as a 1st-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II Study
2015 ◽
Vol 33
(15_suppl)
◽
pp. e14005-e14005